WO2005074922A1 - 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS - Google Patents
1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS Download PDFInfo
- Publication number
- WO2005074922A1 WO2005074922A1 PCT/EP2005/001021 EP2005001021W WO2005074922A1 WO 2005074922 A1 WO2005074922 A1 WO 2005074922A1 EP 2005001021 W EP2005001021 W EP 2005001021W WO 2005074922 A1 WO2005074922 A1 WO 2005074922A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- thieno
- pyrazole
- phenyl
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to thieno-pyrazole derivatives, to a process for their preparation, to pharmaceutical compositions comprising them, and to their use as therapeutic agents, particularly in the treatment of cancer and cell proliferation disorders
- PKs protein kmases
- the enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomeruloneph ⁇ tis and post-surgical stenosis and restenosis PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders
- PKs malfunctioning or deregulation see, for instance,
- Aurora kmases in particular Aurora-2 Aurora-2 was found to be over-expressed in a number of different tumor types Its gene locus maps at 20q13, a chromosomal region frequently amplified in many cancers, including breast [Cancer Res 1999, 59(9), 2041-4] and colon 20q13 amplification correlates with poor prognosis in patients with node-negative breast cancer and increased Aurora-2 expression is indicative of poor prognosis and decreased survival time in bladder cancer patients [J Natl Cancer Inst , 2002, 94(17), 1320- 9].
- the present inventors have now discovered that some thieno-pyrazole compounds, and derivatives thereof, are endowed with protein kinase inhibiting activity, e.g. Aurora kinases inhibiting activity.
- the compounds of this invention are useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosar
- these thieno-pyrazole derivatives are also useful in the treatment of a variety of cell proliferative disorders such as, for instance, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post- surgical stenosis and restenosis.
- the present invention provides a method for treating cell proliferative disorders caused by and/or associated with an altered protein kinase activity, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I)
- R is an optionally substituted aryl or heteroaryl group
- Ri and R 2 represent, the same or different and independently from each other, a hydrogen atom, a straight or branched C 1 -C 3 alkyl or a group -CONH 2 or -CH 2 NR'R" or, taken together with the carbon atom to which they are bonded, R, and R 2 may form a C 3 -C 6 cycloalkyl group; with the proviso that at least one of R ⁇ and R 2 is other than a hydrogen atom, R' and R" represent, the same or different and independently from each other, a hydrogen atom or a straight or branched C 1 -C 3 alkyl group or, taken together with the nitrogen atom to which they are bonded, R' and R" may form a heterocyclic ring of formula
- R'" is a hydrogen atom or a straight or branched C 1 -C 3 alkyl group
- R 3 is a hydrogen or halogen atom or a group selected from hydroxy, cyano, straight or branched C 1 -C 3 alkyl or C r C 3 alkoxy; or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof.
- the cell proliferative disorder is cancer.
- cancer Specific types of cancer that may be treated include carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, and Kaposi's sarcoma.
- the present invention also provides a compound of formula (I)
- R is an optionally substituted aryl or heteroaryl group
- Ri and R 2 represent, the same or different and independently from each other, a hydrogen atom, a straight or branched C C 3 alkyl or a group -CONH 2 or -CH 2 NR'R" or, taken together with the carbon atom to which they are bonded, R, and R 2 may form a C 3 -C 6 cycloalkyl group; with the proviso that at least one of R, and R 2 is other than a hydrogen atom;
- R' and R" represent, the same or different and independently from each other, a hydrogen atom or a straight or branched C r C 3 alkyl group or, taken together with the nitrogen atom to which they are bonded, R' and R" may form a heterocyclic ring of formula wherein R'" is a hydrogen atom or a straight or branched C,-C 3 alkyl group;
- R 3 is a hydrogen or halogen atom or a group
- the present invention also includes methods of synthesizing the thieno-pyrazole compounds of formula (I) and the pharmaceutically acceptable salts, as well as the pharmaceutical compositions comprising them.
- 2-carboxamido-pyrazole and 2-ureido-pyrazole derivatives have been disclosed as protein kinase inhibitors in the international patent applications WO 01/12189, WO 01/12188, WO 02/48114 and WO 02/70515, all in the name of the applicant itself.
- Fused bicyclic compounds comprising pyrazole moieties and possessing kinase inhibitory activity have been also disclosed in WO 00/69846, WO 02/12242, WO 03/028720, WO 03/097610 as well as in WO2004007504 and WO2004013146 applications (respectively claiming priority from US 60/396, 174 of July 17, 2002; and US 60/398, 121 of July 25, 2002) all in the name of the applicant itself.
- 5-phenylsulfonyl-thieno[2,3-c]pyrazole derivatives are also known in the art as synthetic intermediates for the preparation of more complex heterocyclic structures, as reported in Monatshefte fur Chemie 128, 687-696 (1997).
- the compounds of the present invention fall within the scope of the general formula of the aforementioned WO2004013146 but are not specifically exemplified therein.
- the compounds of formula (I) of the invention have asymmetric carbon atoms and may therefore exist as individual optical isomers, as racemic mixtures or as any other mixture comprising a majority of one of the two optical isomers, which are all to be intended as within the scope of the present invention.
- the use as an antitumor agent of all the possible isomers and their admixtures and of both the metabolites and the pharmaceutically acceptable bio-precursors (otherwise referred to as pro-drugs) of the compounds of formula (I) are also within the scope of the present invention.
- Prodrugs are any covalently bonded compounds, which release the active parent drug, according to formula (I), in vivo.
- each form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
- the remaining one has still to be intended as comprised within the scope of the invention:
- aryl group we intend any aromatic carbocyclic ring system of 1 or 2 ring moieties, either fused or linked to each other through a single bond, for instance including phenyl, D- or D-naphthyl or biphenyl groups.
- heteroaryl we intend any aromatic heterocyclic ring which may comprise an optionally benzocondensed 5 or 6 membered heterocycle with from 1 to 3 heteroatoms selected among N, O or S.
- Non limiting examples of heteroaryl groups according to the invention may thus include, for instance, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, phenyl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, quinolinyl, isoquinolinyl, 1 ,2,3-triazolyl, 1-phenyl- 1 ,2,3-triazolyl, and the like.
- C C 3 alkyl or C C 3 alkoxy we intend any of the groups such as methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy and isopropoxy.
- halogen atom we intend a fluorine, chlorine, bromine or iodine atom.
- C 3 -C 6 cycloalkyl we intend any group such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- any of the above aryl or heteroaryl groups may be optionally further substituted in any of their free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, carboxy, cyano, alkyi, polyfluorinated alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; aryl, heterocyclyl, alkyl-heterocyclyl, heterocyclyl-alkyl, amino-alkyl, amino groups and derivatives thereof such as, for instance, alkylamino, dialkylamino, arylamino, diarylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as, for instance, formylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino;
- each of the above substituents may be further substituted by one or more of the aforementioned groups.
- alkyl or alkoxy group we intend, unless otherwise provided, any straight or branched C C 6 alkyl or alkoxy group, hence comprehensive of the aforementioned C C 3 alkyl or alkoxy groups and also comprising n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n- hexyl, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, and the like.
- alkenyl or alkynyl group we intend, unless otherwise provided, any unsaturated straight or branched C 2 -C 5 alkenyl or alkynyl group such as, for instance, vinyl, ally!, 1-propeny!, isopropenyl, 1-, 2- or 3-butenyl, pentenyl, hexenyl, ethynyl, 1- or 2-propynyl, butynyl, pentynyl, hexynyl, and the like.
- polyfluorinated alkyl or alkoxy we intend any straight or branched C C 6 alkyl or alkoxy group as above defined, wherein more than one hydrogen atom is replaced by fluorine atoms such as, for instance, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethyl, 2,2,2-trifluoroethoxy, 1 ,2-difluoroethyl, 1 ,1 ,1 ,3,3,3-hexafluoropropyl-2-yl, and the like.
- heterocyclyl or heterocyclic group we also intend an optionally benzocondensed 4 to 7 membered heterocycle, hence encompassing aromatic heterocyclic groups also known as heteroaryl groups, either saturated or partially unsaturated, with from 1 to 3 heteroatoms selected among N, O and S.
- Examples of these 4 or 7 membered heterocyclic groups are, for instance, 1,3- dioxolane, pyran, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, tetrahydrofuran, hexamethyleneimine, 1 ,4- hexahydrodiazepine, azetidine, and the like.
- cycloalkenyl we intend any of the aforementioned C 3 -C 6 cycloalkyl groups further comprising a double bond such as, for instance, 2-cyclopenten-1-yl, 3- cyclopenten-1-yl, 1-cyclohexen-1-yl, 2 ⁇ cyclohexen-1-yl, 3-cyclohexen-1-yl, and the like.
- any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkylthio, aryloxy, arylalkyloxy, alkylcarbonyloxy and the like, has to be intended as conventionally construed from the parts to which they derive.
- alkoxy-heterocyclyl-alkyl stands for a straight or branched alkyl group substituted by a heterocycle further substituted by alkoxy, wherein alkyl, heterocycle and alkoxy are as above defined.
- alkyl-heterocyclyloxy stands for a heterocyclyloxy group further substituted by alkyl.
- pharmaceutically acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared from an inorganic or organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid.
- organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, trifluoroacetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfo ⁇ ic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, hydroxybuty
- Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compounds of the present invention, for instance by reacting them with the appropriate acid or base.
- a preferred class of compounds of the invention is represented by the derivatives of formula (I) wherein R is a group, optionally further substituted, selected from thienyl, furyl, pyrrolyl and phenyl.
- R is thienyl, furyl, pyrrolyl, N-methyl-pyrrolyl, phenyl and phenyl substituted by halogen atoms, heterocycles, amino-alkyl groups, heterocylyloxy or heterocyclylalkyl groups.
- R is selected from 2-thienyl, 2-furyl, 1 -methyl-pyrrolyl-2-yl, phenyl, 4-fluorophenyl, 4-(1 -methyl-piperidyl-4- yloxy)phenyl, 4-(1-methyl-piperazinyl-4-yl)phenyl, 4-(1-methyl-piperazinyl-4yl-methyl)phenyl 4- (pyrrolidin-l-yl)methyl-phenyl, 4-(piperidin-1-yl)methyl-phenyl, 4-(1-methyl-piperazin-4- yl)methyl-phenyl, 4-(morpholino-1-yl)methyl-phe ⁇ yl, 4-(alkylamino)methyl-phenyl, 4- (dialkylamino)methyl-phenyl or 4-(morpholino-4-yl)phenyl.
- Another preferred class of compounds of the invention is represented by the derivatives of formula (!) wherein one of R ⁇ and R 2 is a hydrogen atom or a methyl group and the remaining one of R, and R 2 is methyl, ethyl or a group -CH 2 NR'R" wherein R' and R" are as set forth above.
- Another preferred class of compounds of the invention is represented by the derivatives of formula (I) wherein Ri and R 2 , together with the carbon atom to which they are attached, form a C 3 -C 6 cycloalkyl group and, even more preferably, cyclopropyl or cyclopentyl.
- R, Ri and R 2 are as set forth above and R 3 represents a hydrogen, fluorine or chlorine atom, or a group selected from hydroxy, methoxy or cyano.
- R 3 represents a hydrogen, fluorine or chlorine atom, or a group selected from hydroxy, methoxy or cyano.
- a further object of the present invention is represented by the process for preparing the compounds of formula (I) and the pharmaceutically acceptable salts thereof, which process comprises: a) reacting a compound of formula (II), wherein Alk stands for a lower alkyl group, with hydrazine or a hydrazine salt and reacting the thus obtained intermediate compound under acidic conditions so as to obtain a compound of formula (III)
- a compound of formula I wherein R is an optionally substituted 4'-(amino- methyl)phenyl group can be optionally prepared by: f) treating derivatives of formula IX, wherein R is a phenyl group substituted at position 4' with a chloromethyl group with ammonia or a primary or secondary amine to deprotect and convert them into a compound of formula I, wherein R is an optionally substituted 4'-(amino-methyl)phenyl group, as shown in the following scheme:
- step (I) of the process the reaction between a compound of formula (II)and hydrazine or a hydrazine salt, for instance hydrazine dihydrochloride or hydrazine sulphate or acetate, can be carried out in the presence of catalytic amounts of an acid such as hydrochloric, acetic or sulphuric acid, or in the presence of catalytic amounts of a Lewis acid such as boron trifluoride dimethyl etherate.
- an acid such as hydrochloric, acetic or sulphuric acid
- a Lewis acid such as boron trifluoride dimethyl etherate.
- this same reaction may be also accomplished in the presence of catalytic amounts of a strong base such as sodium methoxide.
- a strong base such as sodium methoxide.
- the reaction is carried out in a suitable solvent such as, for instance, N,N'- dimethylformamide, tetrahydrofuran, 1,4-dioxane, acetonitrile, water, methanol or ethanol, at a temperature ranging from about room temperature to reflux and for a time varying from about 30 minutes to about 18 hours.
- a suitable solvent such as, for instance, N,N'- dimethylformamide, tetrahydrofuran, 1,4-dioxane, acetonitrile, water, methanol or ethanol, at a temperature ranging from about room temperature to reflux and for a time varying from about 30 minutes to about 18 hours.
- Alk represents a straight or branched lower alkyl group, for instance a C C 6 alkyl group and even more preferably a
- step (a) is carried out by reacting a compound of formula (II) with hydrazine hydrate in methanol, ethanol or tetrahydrofuran at a temperature ranging from room temperature to refluxing temperature.
- the obtained tert-butyl 4-cyano-5-hydrazinothiophene- 2-carboxylate intermediate can be either separated from the reaction medium and further processed as per the working examples or, alternatively, directly processed through cyclization so as to afford the compound of formula (III).
- Cyclization is carried out at a temperature ranging from about 15°C to about 50°C in methanol or ethanol, and in the presence of catalytic amounts of a mineral acid such as hydrochloric or sulphuric acid.
- step (b) of the process the thus obtained thieno-pyrazole derivative of formula (III) is then protected, according to well-known methods, at the pyrazole nitrogen atom.
- the above protection may occur with an alkyl chlorocarbonate, in a suitable solvent such as tetrahydrofuran, dichloromethane, chloroform, acetonitrile, toluene or mixtures thereof, at a temperature ranging from about -5°C to about 35°C and for a time varying from about 30 minutes to about 72 hours, in the presence of an opportune proton scavenger such as triethylamine or diisopropylethylamine.
- step (c) of the process the compound of formula (IV) is then reacted with any suitable acylating agent of formula (V) so as to yield the compound of formula (VI), by working according to methods well known in the art for the preparation of carboxamido derivatives.
- Z represents a halogen atom and, even more preferably, a bromine or chlorine atom.
- the reaction is carried out in a suitable solvent such as, for instance, tetrahydrofuran, dimethylformamide, dichloromethane, chloroform, acetonitrile, toluene or mixtures thereof, at a temperature ranging from about -10°C to reflux and for a time varying from about 30 minutes to about 96 hours, in the presence of an opportune proton scavenger such as triethylamine, N.N-diisopropylethylamine or pyridine.
- a suitable solvent such as, for instance, tetrahydrofuran, dimethylformamide, dichloromethane, chloroform, acetonitrile, toluene or mixtures thereof.
- an opportune proton scavenger such as triethylamine, N.N-diisopropylethylamine or pyridine.
- step (b) the above protection at the pyrazole nitrogen atom, in step (b), is of particular advantage as it prevents that acylation with the compound of formula (V), in step (c), occurs at the pyrazole nitrogen atom.
- step (d) of the process the carboxyester function of the compound of formula (VII) is selectively hydrolized so as to yield the corresponding carboxy group.
- the reaction is carried out under acidic conditions, preferably in the presence of hydrochloric acid in dioxane, by operating at room temperature and for a suitable time, for instance up to 72 hours.
- step (e) of the process the compound of formula (VII) is then reacted with a suitable amino derivative of formula (VIII) so as to lead to the corresponding compound of formula (IX). From the above it is clear to the skilled person that this reaction may be accomplished in a variety of ways and operative conditions, which are widely known in the art for the preparation of carboxamides.
- the reaction between the compounds of formula (VII) and (VIII) can be carried out in the presence of a coupling agent such as, for instance, 2-(1 H-benzotriazol-1-yl)- 1 ,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU), 1 ,3-dicyclohexylcarbodiimide, 1 ,3- diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N- cyclohexylcarbodiimide-N'-propyloxymethyl polystyrene or N-cyclohexylcarbodiimide-N'- methyl polystyrene, in a suitable solvent such as, for instance, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, 1 ,4-dioxane, acetonitrile
- the said reaction is optionally carried out in the presence of a suitable catalyst, for instance 4-dimethylaminopyridine, or in the presence of a further coupling reagent such as N- hydroxybenzotriazole.
- a suitable catalyst for instance 4-dimethylaminopyridine
- a further coupling reagent such as N- hydroxybenzotriazole.
- this same reaction can be also carried out, for example, through a mixed anhydride method, by using an alkyl chloroformate such as ethyl, iso-butyl, or iso-propyl chloroformate, in the presence of a tertiary base such as triethylamine, N,N- diisopropylethylamine or pyridine, in a suitable solvent such as, for instance, toluene, dichloromethane, chloroform, tetrahydrofuran, acetonitrile, diethyl ether, 1 ,4-dioxane
- step (f) of the process the compound of formula (IX) is deprotected at the pyrazole nitrogen atom under basic conditions and by working according to conventional techniques, for instance by treatment with aqueous sodium or potassium hydroxide in the presence of a suitable co-solvent such as methanol, ethanol, dimethylformamide, 1 ,4-dioxane, or by treatment with a tertiary amine such as triethylamine or N,N-diisopropylethylamine and by using an alcohol like methanol or ethanol as the solvent.
- Deprotection may occur at a temperature ranging from about 18°C to refluxing temperature of the solvent, for a time varying from about 30 minutes to about 72 hours.
- step f) of the process the benzylic chlorine atom of the compound of formula (IXa) is substituted by treatament with ammonia or a primary or secondary amine in a suitable solvente like as methanol, ethanol, tetrahydrofuran, dimethylformamide, at a temperature ranging from 0 °C to the reflux temperature of the solvent.
- a suitable solvente like as methanol, ethanol, tetrahydrofuran, dimethylformamide
- step (a) the compound of formula (III) of step (a) may be reacted with an excess of the compound of formula (V), by working as reported in step (c), so as to get the desired functionalization at the amino moiety and, in the meantime, the protection at the pyrazole nitrogen atom.
- a process for preparing the compounds of formula (I) and the pharmaceutically acceptable salts thereof comprises: a') reacting the compound of formula (III) being obtained in step (a) of the process with an excess of a compound of formula (V), wherein R is as set forth above and Z represents a suitable leaving group, so as to obtain a compound of formula (X) b') deprotecting the compound of formula (X) at the pyrazole nitrogen atom, as per step (f) of the process, and further reacting the resultant compound according to the remaining steps (d) and (e).
- All of the compounds of formula (II), (V) and (VIII) are known or can be obtained according to known methods.
- the starting material of formula (II) wherein Alk stands for methyl can be easily obtained as follows, by starting from commercially available ethyl 4-cyano-5- (methylthio)thiophene-2-carboylate:
- hydrolysis of the ethoxycarbonyl group is carried out according to well-known methods, for instance in the presence of aqueous alkaline solutions such as aqueous sodium hydroxide.
- esterification is carried out according to well-known operative conditions, in the presence of an alkylating agent like tert-butyl bromide or di-tertbutyl-dicarbonate, in a suitable solvent such as dimethylformamide or tetrahydrofuran.
- the conversion of the alkylthio group into alkylsulfonyl can be carried in the presence of any opportune oxidizing agent such as, for instance, hydrogen peroxide, 3- chloroperoxybenzoic acid or oxone, in a suitable solvent such as, for instance, dichloromethane, DMF, acetone, toluene, acetonitrile, methanol, ethanol, water, acetic acid, at a temperature ranging from about -10°C to reflux and for a time varying from about 30 minutes to about 4 days.
- a suitable solvent such as, for instance, dichloromethane, DMF, acetone, toluene, acetonitrile, methanol, ethanol, water, acetic acid
- the compounds of formula (I) are active as protein kinase inhibitors, more particularly as Aurora kinases inhibitors and are therefore useful, for instance, to restrict the unregulated proliferation of tumor cells. In therapy, they may be used in the treatment of various tumors, such as those formerly reported, as well as in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth cell proliferation associated with atherosclerosis and post-surgical stenosis and restenosis.
- the inhibiting activity and the potency of selected compounds is determined through a method of assay based on the use of the SPA technology (Amersham Pharmacia Biotech).
- the assay consists of the transfer of radioactivity labelled phosphate moiety by the kinase to a biotinylated substrate.
- the resulting 33P-Iabelled biotinylated product is allowed to bind to streptavidin-coated SPA beads (biotin capacity 130 pmol/mg), and light emitted was measured in a scintillation counter.
- the compounds of the invention were further tested, in vitro, to assess the anti- proliferative effect onto cell cultures.
- the human colon cancer cell line HCT-116 was seeded at 5000 cells/cm2 in 24 wells plate (Costar) using F12 medium (Gibco) supplemented with 10% FCS (EuroClone, Italy) 2 mM L-glutamine and 1 % penicillin/streptomycin and maintained at 37°C, 5% C0 2 and 96% relative humidity. The following day, plates were treated in duplicates with 5ul of an appropriate dilution of compounds starting from a 10 mM stock in DMSO. Two untreated control wells were included in each plate.
- Aurora-2 inhibitory activity See, as an example, the following table I reporting the experimental data of some representative compounds of the invention being tested as Aurora-2 kinase inhibitors (IC 0 nM) and for their cell antiproliferative effect (IC 50 nM). Interestingly, these same derivatives were tested in comparison to a structurally very close compound, herewith defined as Reference compound, which is specifically disclosed in the aforementioned PCT/EP03/07531 patent application - see compound No. 421 of example 6.
- the Aurora-2 inhibitory activity of the compounds of the invention resulted to be constantly and markedly superior that that of the Reference compound.
- those same compounds resulted to possess a cell antiproliferative effect significantly superior than that of the Reference compound being tested in the same conditions.
- the novel compounds of formula (I) of the invention appear to be endowed with a biological profile, considered as a whole, which is unexpectedly superior thant that of the closest compound of WO2004013146and, hence, are particularly advantageous, in therapy, against proliferative disorders associated with an altered Aurora-2 kinase activity.
- the compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, i ⁇ terferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g.
- cytostatic or cytotoxic agents antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, i ⁇ terferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-
- angiogenesis inhibitors angiogenesis inhibitors
- farnesyl transferase inhibitors farnesyl transferase inhibitors
- ras-raf signal transduction pathway inhibitors cell cycle inhibitors
- other cdks inhibitors tubulin binding agents
- topoisomerase I inhibitors topoisomerase II inhibitors
- Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.
- the compounds of formula (I) of the present invention suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.
- a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 30 to about 500 mg per dose, from 1 to 5 times daily. In general lower doses will be administered when a parental route is employed.
- a dose in the range for example, 0.5 mg to 30 mg per kg body weight will be generally used.
- the compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.
- the present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.
- the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form.
- the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
- diluents e.g., lactose, dextrose saccharose, suc
- the liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions.
- the syrups may contain, as a carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.
- the suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydroch ride.
- a pharmaceutically acceptable carrier e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydroch ride.
- the solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.
- the suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
- a pharmaceutically acceptable carrier e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
- Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid / acetonitrile 95:5), and Mobile phase B was water / acetonitrile (5:95). Gradient from 10 to 90% B in 8 minutes, hold 90% B 2 min. UV detection at 220 nm and 254 nm. Flow rate 1 mL/min. Injection volume 10 ⁇ l. Full scan, mass range from 100 to 800 amu. Capillary voltage was 2.5 KV; Source temperature was 120°C; Cone was 10 V. Retention Times (LC-MS Rt) are given in minutes at 220 nm or 254 nm. Mass are given as m/z ratio.
- Example 1 4-Cyano-5-(methylthio)thiophene-2-carboxylic acid Aqueous sodium hydroxide (20% w/w solution, 9 mL) was added to a solution of ethyl 4-cyano-5-(methylthio)thiophene-2-carboxylate (10 g, 44 mmol) in 1 ,4-dioxane (100 mL) at 5°C. After stirring for 4 hours at room temperature, water (500 mL) was added to the reaction mixture and the pH was adjusted to about 2.5 by adding 2N solution of aqueous hydrochloric acid. A white solid was separated by filtration, washed with water and dried under vacuum to give 8.5 g of the title compound.
- ethyl 4-cyano-5-(methylthio)thiophene-2-carboxylate 10 g, 44 mmol
- 1 ,4-dioxane 100 mL
- water 500 mL was added to the reaction mixture and the pH was adjusted
- Example 3 tert-butyl 4-cyano-5-(methylsulfonyl)thiophene-2-carboxylate
- a mixture of tert-butyl 4-cyano-5-(methylthio)thiophene-2-carboxylate (1.4 g, 5.5 mmol) and oxone (14.4 g, 21.5 mmol) in dimethylformamide (100 mL) was stirred at room temperature for 16 hours.
- the reaction mixture was then poured into ice/water (400 mL) and extracted with ethyl acetate. Organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated to dryness to afford 1.5 g of the title compound.
- Example 4 tert-butyl 4-cyano-5-hydrazinothiophene-2-carboxylate A mixture of tert-butyl 4-cyano-5-(methylsulfonyl)thiophene-2-carboxylate (2.0 g, 7.0 mmol) and hydrazine hydrate (1.7 mL) in methyl alcohol (30 mL) was stirred at 60°C for 2 hours. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with water.
- Example 5 tert-butyl 3-amino-1 H-thieno[2,3-c]pyrazole-5-carboxylate
- a mixture of tert-butyl 4-cyano-5-hydrazinothiophene-2-carboxylate (1.0 g, 4.2 mmol) and hydrochloric acid (0.7 mL of a 37% solution) in methyl alcohol (15 mL) was stirred at room temperature for 14 hours.
- the reaction mixture was diluted with ethyl acetate (50 mL) and washed with an aqueous solution of sodium bicarbonate. Organic layer was separated, dried over anhydrous sodium sulfate and evaporated to afford 0.9 g of the title compound.
- Example 8 1-(ethoxycarbonyl)-3-[(4-morpholin-4-ylbenzoyl)amino]-1 H-thieno[2,3-c]pyrazole-5- carboxylic acid hydrochloride 5-tert-butyl 1-ethyl 3-[(4-morpholin-4-ylbenzoyl)amino]-1 H-thieno[2,3-c]pyrazole-1 ,5- dicarboxylate (4.05 g) was added to a solution of hydrochloric acid in dioxane (88 mL, 4N solution). The resulting mixture was stirred at room temperature for 72 hours.
- Example 10 N-(1 -methyl-1 -phenylethyl)-3-[(4-morpholin-4-ylbenzoyl)amino]-1 H-thieno[2,3- c]pyrazole-5-carboxamide
- a suspension of ethyl 5- ⁇ [(1 -methyl-1 -phenylethyl)amino]carbonyl ⁇ -3-[(4-morpholin-4- ylbenzoyl)amino]-1 H-thieno[2,3-c]pyrazo!e-1-carboxylate (3.71 g, 6.6 mmol) in methanol (MeOH, 70 mL) and triethylamine (TEA, 7 mL) was stirred at 70° C for 5 hours.
- Example 15 5-tert-butyl 1-ethyl 3-[(4-chloromethyl-benzoyl)amino]-1 H-thieno[2,3-c]pyrazole-1 ,5- dicarboxylate 4-Chloromethylbenzoyl chloride (5.42 g 28.7 mmol) was added to a suspension of tert-butyl 3-amino-1 H-thieno[2,3-c]pyrazole-5-carboxylate (5.94 g, 19.1 mmol) in dry DCM (150 mL) and 2,4,6-collidine (6.94 g, 57.3 mmol) under stirring at 20°C. The resulting suspension was stirred for 3 hours at room temperature.
- Example 17 ethyl 5- ⁇ [(1 -methyl-1 -phenylethyl)amino]carbonyl ⁇ -3-[(4-chloromethyl-benzoyl)amino]- 1H-thieno[2,3-c]pyrazole-1 -carboxylate
- 1-(ethoxycarbonyl)-3-[(4- chloromethyl-benzoyl)amino]-1 H-thieno[2,3-c]pyrazole-5-carboxylic (2.88 mg, 7.07 mmol) and N,N'-di ⁇ sopropy!ethy!amine (18.2 mL, 10.6 mmol) in 150 mL of dichloromethane
- Example 18 3-(4-Pyrrolidin-1-ylmethyl-benzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1- methyl-1-phenyl-ethyl)-amide (37) Pirrolidine (1.81 mL, 21.8 mmol), was added to a suspension of ethyl 5- ⁇ [(1 -methyl-1 - phenylethyl)amino]carbonyl ⁇ -3-[(4-chloromethyl-benzoyl)amino]-1 H-thieno[2,3-c]pyrazole-1- carboxylate (3.80 mg, 7.25 mmol) in 100 mL of dry ethanol.
- Example 19 By operating as above reported in Example 10, the following compounds were analogously prepared by starting from the suitable intermediate derivatives: 100) 3-(4-methoxy-benzoylamino)-1 H-thieno[2,3-c]pyrazole-5-carboxylic acid (1- methyl-1-phenyl-ethyl)-amide; [M+Hf 435. 101) 3-(3-methoxy-benzoylamino)-1 H-thieno[2,3-c]pyrazole-5-carboxylic acid (1- methyl-1-phenyl-ethyl)-amide; [M+H] + 435.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05701307A EP1711177B1 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS |
JP2006551790A JP4908233B2 (en) | 2004-02-03 | 2005-02-02 | 1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors |
NZ548896A NZ548896A (en) | 2004-02-03 | 2005-02-02 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
PL05701307T PL1711177T3 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS |
SI200530297T SI1711177T1 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS |
EA200601418A EA011032B1 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO[2.3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS |
CA2555262A CA2555262C (en) | 2004-02-03 | 2005-02-02 | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
AP2006003701A AP2006003701A0 (en) | 2004-02-03 | 2005-02-02 | 1H-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors |
DK05701307T DK1711177T3 (en) | 2004-02-03 | 2005-02-02 | 1H-thieno-2,3-c-pyrazole derivatives useful as kinase I inhibitors |
DE602005007181T DE602005007181D1 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO 2,3-C-PYRAZOL DERIVATIVES AS KINASE I HEMMER |
MXPA06008787A MXPA06008787A (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS. |
AU2005210114A AU2005210114B2 (en) | 2004-02-03 | 2005-02-02 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
CN200580005922.0A CN1946395B (en) | 2004-02-03 | 2005-02-02 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
BRPI0507375-8A BRPI0507375A (en) | 2004-02-03 | 2005-02-02 | 1h-thieno [2,3-c] pyrazole derivatives useful as kinase inhibitors |
IL177141A IL177141A0 (en) | 2004-02-03 | 2006-07-27 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS |
TNP2006000244A TNSN06244A1 (en) | 2004-02-03 | 2006-08-03 | 1H-THIENO [2,3-C] PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS |
NO20063768A NO20063768L (en) | 2004-02-03 | 2006-08-23 | 1H-thieno [2,3c] pyrazole derivatives useful as kinase inhibitors |
HK07106106.1A HK1101343A1 (en) | 2004-02-03 | 2007-06-07 | 1h-thieno(2,3-c)pyrazole derivatives useful as kinase inhibitors 1h-[23-c] |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54145204P | 2004-02-03 | 2004-02-03 | |
US60/541,452 | 2004-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005074922A1 true WO2005074922A1 (en) | 2005-08-18 |
Family
ID=34837492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/001021 WO2005074922A1 (en) | 2004-02-03 | 2005-02-02 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS |
Country Status (38)
Country | Link |
---|---|
US (2) | US8138217B2 (en) |
EP (1) | EP1711177B1 (en) |
JP (1) | JP4908233B2 (en) |
KR (1) | KR20060124734A (en) |
CN (1) | CN1946395B (en) |
AP (1) | AP2006003701A0 (en) |
AR (1) | AR047531A1 (en) |
AT (1) | ATE396724T1 (en) |
AU (1) | AU2005210114B2 (en) |
BR (1) | BRPI0507375A (en) |
CA (1) | CA2555262C (en) |
CR (1) | CR8546A (en) |
CY (1) | CY1108246T1 (en) |
DE (1) | DE602005007181D1 (en) |
DK (1) | DK1711177T3 (en) |
DO (1) | DOP2005000014A (en) |
EA (1) | EA011032B1 (en) |
EC (1) | ECSP066767A (en) |
ES (1) | ES2307144T3 (en) |
GE (1) | GEP20094633B (en) |
GT (1) | GT200500020A (en) |
HK (1) | HK1101343A1 (en) |
IL (1) | IL177141A0 (en) |
MA (1) | MA28429B1 (en) |
MX (1) | MXPA06008787A (en) |
NO (1) | NO20063768L (en) |
NZ (1) | NZ548896A (en) |
PA (1) | PA8622801A1 (en) |
PE (1) | PE20051095A1 (en) |
PL (1) | PL1711177T3 (en) |
PT (1) | PT1711177E (en) |
SI (1) | SI1711177T1 (en) |
TN (1) | TNSN06244A1 (en) |
TW (1) | TW200526204A (en) |
UA (1) | UA86223C2 (en) |
UY (1) | UY28738A1 (en) |
WO (1) | WO2005074922A1 (en) |
ZA (1) | ZA200606179B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007009898A1 (en) * | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
WO2007039773A1 (en) * | 2005-10-06 | 2007-04-12 | Merck Sharp & Dohme Limited | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors |
WO2007113198A2 (en) * | 2006-03-30 | 2007-10-11 | Nerviano Medical Sciences S.R.L. | Use of a kinase inhibitor for the treatment of particular resistant tumors |
WO2007138017A1 (en) * | 2006-05-31 | 2007-12-06 | Nerviano Medical Sciences S.R.L. | 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
FR2904626A1 (en) * | 2006-08-03 | 2008-02-08 | Sanofi Aventis | PYRAZOLO [4.3] THIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2009138440A1 (en) * | 2008-05-15 | 2009-11-19 | Nerviano Medical Sciences S.R.L. | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8278450B2 (en) | 2007-04-18 | 2012-10-02 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
WO2019024809A1 (en) * | 2017-08-01 | 2019-02-07 | 正大天晴药业集团股份有限公司 | Bicyclic compound acting as rorγ inhibitor |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0312961A (en) * | 2002-07-25 | 2005-06-14 | Pharmacia Italia Spa | Pyrazole heterocyclic condensed derivatives as kinase inhibitors |
KR100923540B1 (en) | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-Acylhydrazinecarbonyl-3,4-disubstituted pyrazole derivatives and preparation thereof |
HRP20221356T1 (en) * | 2012-04-05 | 2022-12-23 | Nerviano Medical Sciences S.R.L. | New alkylating agents |
CN111542529B (en) * | 2017-11-30 | 2023-06-30 | 韩美药品株式会社 | Thieno [3,2-D ] pyrimidine compounds having protein kinase inhibitory activity |
CN113072562B (en) * | 2021-04-06 | 2022-01-14 | 山东大学 | GSK-3 beta inhibitor and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004007504A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
WO2004013146A1 (en) * | 2002-07-25 | 2004-02-12 | Pharmacia Italia S.P.A | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0234622B1 (en) | 1986-02-19 | 1990-06-27 | Duphar International Research B.V | New thio compounds having fungicidal activity |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
PL353455A1 (en) | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
KR100904157B1 (en) * | 2000-08-10 | 2009-06-23 | 파마시아 이탈리아 에스.피.에이. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP1345909A1 (en) | 2000-11-27 | 2003-09-24 | Pharmacia Italia S.p.A. | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
WO2002070515A2 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia Spa | Chromane derivatives, process for their preparation and their use as antitumor agents |
CZ2004359A3 (en) | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazole derivatives exhibiting kinase inhibitor activity, process of their preparation and pharmaceutical compositions in which the derivatives are comprised |
WO2003097610A1 (en) * | 2002-05-17 | 2003-11-27 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050026984A1 (en) * | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
-
2005
- 2005-01-28 TW TW094102761A patent/TW200526204A/en unknown
- 2005-02-02 AR ARP050100399A patent/AR047531A1/en not_active Application Discontinuation
- 2005-02-02 UA UAA200609515A patent/UA86223C2/en unknown
- 2005-02-02 JP JP2006551790A patent/JP4908233B2/en not_active Expired - Fee Related
- 2005-02-02 PE PE2005000121A patent/PE20051095A1/en not_active Application Discontinuation
- 2005-02-02 GE GEAP20059600A patent/GEP20094633B/en unknown
- 2005-02-02 WO PCT/EP2005/001021 patent/WO2005074922A1/en active IP Right Grant
- 2005-02-02 MX MXPA06008787A patent/MXPA06008787A/en active IP Right Grant
- 2005-02-02 AU AU2005210114A patent/AU2005210114B2/en not_active Ceased
- 2005-02-02 EA EA200601418A patent/EA011032B1/en not_active IP Right Cessation
- 2005-02-02 EP EP05701307A patent/EP1711177B1/en active Active
- 2005-02-02 BR BRPI0507375-8A patent/BRPI0507375A/en not_active IP Right Cessation
- 2005-02-02 PT PT05701307T patent/PT1711177E/en unknown
- 2005-02-02 NZ NZ548896A patent/NZ548896A/en unknown
- 2005-02-02 ES ES05701307T patent/ES2307144T3/en active Active
- 2005-02-02 KR KR1020067017754A patent/KR20060124734A/en not_active Application Discontinuation
- 2005-02-02 AP AP2006003701A patent/AP2006003701A0/en unknown
- 2005-02-02 DK DK05701307T patent/DK1711177T3/en active
- 2005-02-02 PL PL05701307T patent/PL1711177T3/en unknown
- 2005-02-02 DE DE602005007181T patent/DE602005007181D1/en active Active
- 2005-02-02 AT AT05701307T patent/ATE396724T1/en active
- 2005-02-02 CA CA2555262A patent/CA2555262C/en not_active Expired - Fee Related
- 2005-02-02 CN CN200580005922.0A patent/CN1946395B/en not_active Expired - Fee Related
- 2005-02-02 SI SI200530297T patent/SI1711177T1/en unknown
- 2005-02-02 DO DO2005000014A patent/DOP2005000014A/en unknown
- 2005-02-03 US US11/050,360 patent/US8138217B2/en not_active Expired - Fee Related
- 2005-02-03 UY UY28738A patent/UY28738A1/en not_active Application Discontinuation
- 2005-02-03 PA PA20058622801A patent/PA8622801A1/en unknown
- 2005-02-03 GT GT200500020A patent/GT200500020A/en unknown
-
2006
- 2006-07-26 ZA ZA200606179A patent/ZA200606179B/en unknown
- 2006-07-27 IL IL177141A patent/IL177141A0/en unknown
- 2006-08-03 MA MA29227A patent/MA28429B1/en unknown
- 2006-08-03 TN TNP2006000244A patent/TNSN06244A1/en unknown
- 2006-08-03 CR CR8546A patent/CR8546A/en not_active Application Discontinuation
- 2006-08-10 EC EC2006006767A patent/ECSP066767A/en unknown
- 2006-08-23 NO NO20063768A patent/NO20063768L/en not_active Application Discontinuation
-
2007
- 2007-06-07 HK HK07106106.1A patent/HK1101343A1/en not_active IP Right Cessation
-
2008
- 2008-08-07 CY CY20081100834T patent/CY1108246T1/en unknown
-
2012
- 2012-02-24 US US13/404,697 patent/US8481584B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004007504A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
WO2004013146A1 (en) * | 2002-07-25 | 2004-02-12 | Pharmacia Italia S.P.A | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943654B2 (en) | 2005-07-19 | 2011-05-17 | Nerviano Medical Sciences S.R.L. | 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
WO2007009898A1 (en) * | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
JP2009511462A (en) * | 2005-10-06 | 2009-03-19 | メルク シャープ エンド ドーム リミテッド | Use of condensed pyrrole carboxylic acids to treat neurodegeneration and psychiatric disorders as D-amino acid oxidase inhibitors |
WO2007039773A1 (en) * | 2005-10-06 | 2007-04-12 | Merck Sharp & Dohme Limited | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7803829B2 (en) | 2006-03-30 | 2010-09-28 | Nerviano Medical Sciences S.R.L. | Use of a kinase inhibitor for the treatment of particular resistant tumors |
WO2007113198A3 (en) * | 2006-03-30 | 2008-03-20 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
JP2009534307A (en) * | 2006-03-30 | 2009-09-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Use of kinase inhibitors for the treatment of certain resistant tumors |
WO2007113198A2 (en) * | 2006-03-30 | 2007-10-11 | Nerviano Medical Sciences S.R.L. | Use of a kinase inhibitor for the treatment of particular resistant tumors |
US8119641B2 (en) | 2006-05-31 | 2012-02-21 | Nerviano Medical Sciences S.R.L. | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors |
WO2007138017A1 (en) * | 2006-05-31 | 2007-12-06 | Nerviano Medical Sciences S.R.L. | 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
US7772261B2 (en) | 2006-08-03 | 2010-08-10 | Sanofi-Aventis | Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapeutic application thereof |
WO2008015340A3 (en) * | 2006-08-03 | 2009-04-16 | Sanofi Aventis | Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapuetic application thereof |
JP2009545576A (en) * | 2006-08-03 | 2009-12-24 | サノフイ−アベンテイス | Pyrazolo [4,3-d] thiazole derivatives and their preparation and their therapeutic application |
FR2904626A1 (en) * | 2006-08-03 | 2008-02-08 | Sanofi Aventis | PYRAZOLO [4.3] THIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
US8278450B2 (en) | 2007-04-18 | 2012-10-02 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2009138440A1 (en) * | 2008-05-15 | 2009-11-19 | Nerviano Medical Sciences S.R.L. | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
AU2009248060B2 (en) * | 2008-05-15 | 2013-11-14 | Nerviano Medical Sciences S.R.L. | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
EA019901B1 (en) * | 2008-05-15 | 2014-07-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
US8809337B2 (en) | 2008-05-15 | 2014-08-19 | Nerviano Medical Sciences S.R.L. | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
AU2010229144B2 (en) * | 2009-03-23 | 2012-07-12 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
US8569512B2 (en) | 2009-03-23 | 2013-10-29 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
WO2019024809A1 (en) * | 2017-08-01 | 2019-02-07 | 正大天晴药业集团股份有限公司 | Bicyclic compound acting as rorγ inhibitor |
US11466024B2 (en) | 2017-08-01 | 2022-10-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicylic compound acting as an inhibitor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8481584B2 (en) | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | |
US7582628B2 (en) | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
US7786048B2 (en) | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | |
JP5303271B2 (en) | 1H-thieno [2,3-c] pyrazole compounds useful as kinase inhibitors | |
EP2058315A1 (en) | 1H-Furo[3,2-C]Pyrazoles active as aurora kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 177141 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06074315 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4402/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501506 Country of ref document: PH Ref document number: PA/a/2006/008787 Country of ref document: MX Ref document number: 2555262 Country of ref document: CA Ref document number: 548896 Country of ref document: NZ Ref document number: DZP2005000393 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006551790 Country of ref document: JP Ref document number: 2005210114 Country of ref document: AU Ref document number: CR2006-008546 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005701307 Country of ref document: EP Ref document number: 200580005922.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005210114 Country of ref document: AU Date of ref document: 20050202 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005210114 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067017754 Country of ref document: KR Ref document number: 9600 Country of ref document: GE Ref document number: 1200601444 Country of ref document: VN Ref document number: 200601418 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005701307 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067017754 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0507375 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005701307 Country of ref document: EP |